Sign in
Taking peopleNo phase

Studying fat-derived cell injections in people with knee osteoarthritis

Observes cells and joint fluid changes after fat-derived cell injections in knee osteoarthritis.

Key facts

Who runs it
Yonsei University
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
SVF Cellular Composition, Secretome, and Responses in Knee Osteoarthritis
Status
Recruiting
People taking part
20 people, planned
Started
1 Nov 2026
Expected to end
30 Sept 2028
Type of study
Observational
Treatments tested
  • Autologous adipose-derived stromal vascular fraction intra-articular injection
Record updated
27 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with knee osteoarthritis who are already planned to get an injection of their own fat-derived cells (SVF) into the knee. It only observes; it does not assign treatment.

Age
40 to 75 years
Sex
All sexes
Disease stage
Primary knee osteoarthritis, Kellgren-Lawrence grade II or III in the target knee. Knee pain for at least 3 months, with activity pain of at least 4/10.
Earlier treatment
Symptoms must continue despite conservative (non-surgical) therapy. A doctor must already have decided on the SVF injection. No knee replacement, no knee surgery or arthroscopy within 6 months, no steroid or PRP injection within 3 months, no hyaluronic acid injection within 1 month, no cell or regenerative injection within 6 months.

Main reasons for not taking part

  • Kellgren-Lawrence grade I or IV, or arthritis from another cause such as infection, rheumatoid arthritis or gout
  • BMI ≥35 kg/m²
  • Active infection, or severe heart, liver or kidney disease
  • Active cancer under treatment
  • Pregnancy or breastfeeding

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Age 40-75 years at written consent; all sexes
  • ACR-defined primary knee osteoarthritis; target-knee pain for at least 3 months
  • Target-knee Kellgren-Lawrence grade II or III
  • Baseline activity pain VAS at least 4/10
  • Persistent symptoms despite conservative therapy; prior clinical decision for SVF injection
  • Voluntary written informed consent. 7. Ability to comply with follow-up and assessments

Who cannot take part

  • BMI ≥35 kg/m². 5. Prior total/partial target-knee arthroplasty
  • Target-knee surgery/arthroscopy within 6 months before screening. 7. Target-knee steroid/PRP injection within 3 months before screening. 8. Target-knee hyaluronic acid injection within 1 month before screening. 9. Target-knee cell therapy/SVF/other regenerative injection within 6 months before screening
  • Relevant joint disease affecting assessment: recurrent pseudogout, intra-articular fracture, hemochromatosis, Wilson disease, inherited connective-tissue disease, or other significant disease
  • Active systemic infection or local infection at donor site/target knee. 11. Severe cardiovascular/hepatic/renal or uncontrolled systemic disease increasing procedural risk
  • Active malignancy under treatment or investigator-determined unsuitable cancer history
  • Inadequate donor fat for safe liposuction. 16. Cognitive/psychiatric impairment or alcohol/drug dependence preventing understanding/cooperation
  • Target-knee Kellgren-Lawrence grade I or IV
  • Secondary arthritis (infectious, rheumatoid, gouty, reactive, or other causes)
  • Inability to undergo protocol knee radiographs. 14. Pregnancy/breastfeeding

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 40 and 75 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This prospective, single-center observational study will enroll 20 adults aged 40 to 75 years with Kellgren-Lawrence grade II or III knee osteoarthritis who have already been scheduled for an intra-articular injection of autologous adipose-derived stromal vascular fraction (SVF) as clinical care. The study does not assign treatment, use a control group, or randomize participants.

Read full original descriptionShow less

After preparation of the therapeutic SVF, residual adipose tissue will be processed independently with a new disposable kit to obtain research-only SVF. No additional adipose tissue will be harvested for research, and research-only SVF will not be injected. Cellular composition and secretome characteristics of research-only SVF will be measured. Synovial fluid biomarkers will be assessed before injection and at 6 months using the same 12-analyte panel. Patient-reported outcomes and knee radiographs will also be compared between baseline and 6 months. CGBio provides research funding and research-only processing kits without involvement in study conduct, analysis, or publication decisions.

The group in the trial

  • Knee osteoarthritis treated with autologous SVF

    Adults aged 40-75 with Kellgren-Lawrence grade II or III primary knee osteoarthritis and a clinical decision for autologous SVF injection made before research enrollment. Biological, clinical, and radiographic outcomes are observed through 6 months.

    Treatment: Autologous adipose-derived stromal vascular fraction intra-articular injection

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Cellular Composition and Secretome Characteristics of Autologous Adipose-Derived Stromal Vascular Fraction and Biological and Clinical Responses Following Intra-Articular Injection in Patients With Knee Osteoarthritis: A Prospective Observational Study
Plain-language title
Studying fat-derived cell injections in people with knee osteoarthritisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07898501, who can take part
Record updated
27 October 2026